소목, 희첨 및 세포침투성 HSP27 융합단백질을 포함하는 항염증 피부외용제 조성물
    91.
    发明公开
    소목, 희첨 및 세포침투성 HSP27 융합단백질을 포함하는 항염증 피부외용제 조성물 有权
    含有CAESAPINIA SAPPAN,SIEGESBECKIA GLABRESCENS MAKINO和细胞转导热休克蛋白的抗炎性皮肤组合物27融合蛋白

    公开(公告)号:KR1020110136518A

    公开(公告)日:2011-12-21

    申请号:KR1020100056593

    申请日:2010-06-15

    CPC classification number: A61K36/48 A61K8/97 A61K36/28 Y10S514/844 Y10S514/857

    Abstract: PURPOSE: An external use skin composition containing Caesapinia sappan L. extract and cell permeable HSP27 fusion protein is provided to suppress edema and to ensure anti-inflammation. CONSTITUTION: An external use composition for anti-inflammation contains each 0.001-50 wt% of Caesapinia sappan L. extract, Siegesbeckia glabrescens Makino extract, and cell permeable HSP27 fusion protein. The cell permeable HSP27 fusion protein is Pep-HSP27 fusion protein. The external use skin composition is manufactured in the form of a lotion, gel, water soluble liquid, cream, essence, and water-in-oil type or oil-in-water formulation. The composition is a pharmaceutical or cosmetic composition.

    Abstract translation: 目的:提供含有辣椒碱提取物和细胞渗透性HSP27融合蛋白的外用皮肤组合物,以抑制水肿并确保抗炎。 构成:用于抗炎的外用组合物含有Caesapinia sappan L.提取物,Siegesbeckia glabrescens Makino提取物和细胞渗透性HSP27融合蛋白的0.001-50重量%。 细胞渗透性HSP27融合蛋白是Pep-HSP27融合蛋白。 外用皮肤组合物以洗剂,凝胶,水溶性液体,霜剂,精华油和油包水型或水包油制剂的形式制造。 组合物是药物或化妆品组合物。

    희첨 및 세포침투성 HSP27 융합단백질을 포함하는 항염증 피부외용제 조성물
    92.
    发明公开
    희첨 및 세포침투성 HSP27 융합단백질을 포함하는 항염증 피부외용제 조성물 无效
    含有SIEGESBECKIA GLABRESCENS MAKINO和细胞转导热休克蛋白27抗融合蛋白的抗炎性皮肤组合物

    公开(公告)号:KR1020110136372A

    公开(公告)日:2011-12-21

    申请号:KR1020100056324

    申请日:2010-06-15

    Abstract: PURPOSE: An external use composition containing Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein is provided to effectively treat atopic dermatitis and acne. CONSTITUTION: An external use composition for anti-inflammation contains 0.001-50 wt% of Siegesbeckia glabrescens Makino extract and cell permeable HSP27 fusion protein. The composition is a pharmaceutical composition or cosmetic composition. The composition is manufactured in the form of a tonic, lotion, emulsion, cream, ointment, gel, spray, mousse, capsule, or plaster. The daily dose of the composition is 0.0001-100 mg/kg.

    Abstract translation: 目的:提供含有Siegesbeckia glabrescens Makino提取物和细胞渗透性HSP27融合蛋白的外用组合物,有效治疗特应性皮炎和痤疮。 构成:用于抗炎的外用组合物含有0.001-50wt%的Siegesbeckia glabrescens Makino提取物和细胞可渗透的HSP27融合蛋白。 该组合物是药物组合物或化妆品组合物。 组合物以补品,洗剂,乳剂,霜剂,软膏,凝胶,喷雾剂,摩丝,胶囊或石膏的形式制备。 组合物的日剂量为0.0001-100mg / kg。

    까실쑥부쟁이 추출물을 포함하는 당뇨합병증 치료 또는 예방용 조성물
    94.
    发明授权
    까실쑥부쟁이 추출물을 포함하는 당뇨합병증 치료 또는 예방용 조성물 有权
    用于预防或改善糖尿病诱导的包含ASTER AGERATOIDES萃取物的组合物

    公开(公告)号:KR101083832B1

    公开(公告)日:2011-11-18

    申请号:KR1020100006836

    申请日:2010-01-26

    Abstract: 본 발명은 까실쑥부쟁이 추출물을 유효성분으로 포함하는 당뇨합병증 치료 또는 예방용 조성물에 관한 것이다. 상기 까실쑥부쟁이 추출물은 항산화 활성과 알도스 환원효소 억제활성 및 최종당화산물 억제작용이 우수한 것으로 확인되었을 뿐만 아니라, 천연물 추출물이므로 부작용과 안전성 관련 문제가 거의 없으므로, 이를 유효성분으로 포함하는 상기 약학 조성물 또는 건강 기능성 식품 조성물은 당뇨합병증의 치료, 예방 또는 개선을 위하여 사용될 수 있다.

    감초 추출물 성분인 Isoangustone A를 함유하는 신장섬유증 또는 사구체경화증 억제용 조성물

    公开(公告)号:KR1020110060993A

    公开(公告)日:2011-06-09

    申请号:KR1020090117494

    申请日:2009-12-01

    Abstract: PURPOSE: A composition containing isoangustone A is provided to reduce collagen generation and to reduce tissue inhibitor of metalloproteinase type 2(TIMP-2) activity. CONSTITUTION: A composition for suppressing renalfibrosis or glomerulsclerosis contains isoangustone A which is an ingredient of Glycyrrhiza uralensis extract. Isoangustone A has a structure of chemical formula I. A method for isolating isoangustone A comprises: a step of extracting Glycyrrhiza uralensis roots using a solvent of hexane and ethanol by sonication for one hour; a step of decompression-concentrating the extract to prepare crude extract; and a step of performing HSCCC(High-speed countercurrent chromatography).

    Abstract translation: 目的:提供含有异黄酮酮A的组合物以减少胶原蛋白的产生并减少2型金属蛋白酶(TIMP-2)活性的组织抑制剂。 构成:用于抑制肾结石病或肾小球硬化的组合物含有作为甘草提取物成分的异黄酮A。 异黄酮A具有化学式I的结构。异洋ust酮A的分离方法包括:使用己烷和乙醇的溶剂通过超声处理提取甘草根1小时的步骤; 减压浓缩提取物制备粗提物的步骤; 和进行HSCCC(高速逆流色谱法)的工序。

    구멍쇠미역(Agarum clathratum) 추출물을 포함하는 치매 예방 또는 치료 및 인지능 개선용 약학적 조성물 또는 기능성 식품 조성물
    96.
    发明公开
    구멍쇠미역(Agarum clathratum) 추출물을 포함하는 치매 예방 또는 치료 및 인지능 개선용 약학적 조성물 또는 기능성 식품 조성물 有权
    用于预防或治疗感染的药物或功能食品组合物,并提高包含Agarum clathratum提取物的认知能力

    公开(公告)号:KR1020110045746A

    公开(公告)日:2011-05-04

    申请号:KR1020090102442

    申请日:2009-10-27

    Abstract: PURPOSE: A pharmaceutical or functional food composition containing Agarum clathratum extract is provided to enhance acetylcholine concentration and to prevent and treat Alzheimer's disease. CONSTITUTION: A pharmaceutical composition or functional food composition for preventing or treating dementia contains 0.1-99 weight% of Agarum clathratum extract. The Agarum clathratum extract is isolated using water or 50-100% low alcohol of C1-C4. A pharmaceutical composition or functional food composition for improving cognition contains 0.01-15 weight% of the composition .The pharmaceutical composition further contains pharmaceutically acceptable carrier, diluent, or excipient.

    Abstract translation: 目的:提供含有Agarum clathratum提取物的药物或功能性食品组合物,以提高乙酰胆碱浓度并预防和治疗阿尔茨海默病。 构成:用于预防或治疗痴呆的药物组合物或功能性食品组合物含有0.1-99重量%的琼脂提取物。 Agarum clathratum提取物用水或50-100%的低级醇C1-C4分离。 用于改善认知的药物组合物或功能食品组合物含有0.01-15重量%的组合物。药物组合物还含有药学上可接受的载体,稀释剂或赋形剂。

    리코칼콘 A를 포함하는 항염증 조성물
    98.
    发明公开
    리코칼콘 A를 포함하는 항염증 조성물 无效
    含有LICOCHALCONE A的抗炎组合物

    公开(公告)号:KR1020100077553A

    公开(公告)日:2010-07-08

    申请号:KR1020080135520

    申请日:2008-12-29

    Abstract: PURPOSE: A composition containing licochalcone A is provided to prevent and treat sepsis without toxic effects. CONSTITUTION: A pharmaceutical composition for preventing and treating sepsis contains licochalcone A or a pharmaceutically acceptable salt thereof as an active ingredient. Licochalcone A is a major flavonoid isolated from Glycyrrhizae radix. The content of licochalcone A is 0.01-99.9 weight%. The pharmaceutical composition is used in the form of a powder, granule, tablet, capsule, suspension, emulsion, syrup, aerosol, external use formulation, suppository, or injection.

    Abstract translation: 目的:提供含有吡草酮A的组合物,以预防和治疗无毒性的败血症。 构成:用于预防和治疗败血症的药物组合物含有吡罗昔酮A或其药学上可接受的盐作为活性成分。 Licochalcone A是从甘草中分离的主要类黄酮。 查尔酮A的含量为0.01-99.9重量%。 药物组合物以粉末,颗粒,片剂,胶囊,悬浮液,乳剂,糖浆,气雾剂,外用制剂,栓剂或注射剂的形式使用。

    흰색 감국 추출물을 포함하는 뇌허혈 질환 예방 또는 개선용 조성물
    99.
    发明公开
    흰색 감국 추출물을 포함하는 뇌허혈 질환 예방 또는 개선용 조성물 有权
    用于预防或改善含有CHRYSANTHEMUM INDICUM VAR的提取物的脑缺血病的组合物。 ALBESCENS

    公开(公告)号:KR1020090076195A

    公开(公告)日:2009-07-13

    申请号:KR1020080001996

    申请日:2008-01-08

    Abstract: A composition for preventing or treating brain ischemia diseases, which contains white Chrysanthemum indicum Var. albescens as an active ingredient is provided to prevent nerve injury of CA1 area of brain hippocampus. A composition for preventing and treating brain ischemia diseases comprises 0.001-99.99 weight% of Chrysanthemum indicum var. albescens extract as an active ingredient. The brain ischemia diseases are cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage and white matter. The Chrysanthemum indicum var. albescens extract is isolated with 30-80% of alcohol solution of 1-5 carbon atoms. The composition further comprises a carrier, excipient, and diluents. The composition is used in a form of powder, granule, tablet, suspension, emulsion or syrup.

    Abstract translation: 一种预防或治疗脑缺血疾病的组合物,其含有白菊花Var。 提供albescens作为活性成分,以防止脑海马CA1区域的神经损伤。 用于预防和治疗脑缺血疾病的组合物包含菊花变种的0.001-99.99重量% 白花提取物作为活性成分。 脑缺血病是脑梗塞,脑出血,蛛网膜下腔出血和白质。 菊花变种 用30-80%的1-5个碳原子的醇溶液分离白鼬提取物。 组合物还包含载体,赋形剂和稀释剂。 该组合物以粉末,颗粒,片剂,悬浮液,乳剂或糖浆的形式使用。

    천궁분획물에서 분리한 리구스틸라이드를 유효성분으로포함하는 비만 억제용 조성물
    100.
    发明公开
    천궁분획물에서 분리한 리구스틸라이드를 유효성분으로포함하는 비만 억제용 조성물 无效
    用于抑制包含从CNIDI RHIZOMA分离物中分离的LIGESTILIDE的有效成分的组合物作为有效组合物

    公开(公告)号:KR1020090028082A

    公开(公告)日:2009-03-18

    申请号:KR1020070093379

    申请日:2007-09-14

    Abstract: A manufacturing method of anti-obesity composition is provided to have excellent obesity inhibition effect using ligustilide separated from the Cnidii Rhizoma fractions. A manufacturing method of anti-obesity composition comprises steps of: preparing cnidii Rhizoma; dipping prepared Cnidii Rhizoma in ethanol, extracting it and manufacturing Cnidii Rhizoma extract; manufacturing the Cnidii Rhizoma extraction concentrate by concentrating the Cnidii Rhizoma extract; putting water into the manufactured Cnidii Rhizoma extraction concentrate, partitioning it into hexane, concentrating it and manufacturing the Cnidii Rhizoma fractions; and obtaining active compound containing ligustilide component by gushing out the manufactured Cnidii Rhizoma fractions to silica gel column.

    Abstract translation: 提供了一种抗肥胖组合物的制造方法,其具有优异的抑制肥胖效果的作用。 抗肥胖组合物的制造方法包括以下步骤:制备枸杞子; 浸泡在乙醇中制备,提取并制备枸杞提取物; 通过浓缩Cnidii Rhizoma提取物制备Cnidii Rhizoma提取浓缩物; 将水倒入生产的Cnidii Rhizoma提取浓缩物中,将其分配成己烷,浓缩并制备Cnidii Rhizoma级分; 并通过将所制造的Cnidii Rhizoma级分喷出到硅胶柱中,获得含有活性化合物的ligustilide组分。

Patent Agency Ranking